Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05186462 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Intravenous: PF-05186462 | ACTIVE_COMPARATOR | - |
| Oral: PF-05186462 | ACTIVE_COMPARATOR | - |
| Intravenous: PF-05089771 | ACTIVE_COMPARATOR | - |
| Oral: PF-05089771 | ACTIVE_COMPARATOR | - |
| Intravenous: PF-05150122 | ACTIVE_COMPARATOR | - |
| Oral: PF-05150122 | ACTIVE_COMPARATOR | - |
| Intravenous: PF-05241328 | ACTIVE_COMPARATOR | - |
| Oral: PF-05241328 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-05186462 | DRUG | single intravenous infusion of 100 microgram |
| PF-05089771 | DRUG | single intravenous infusion of 100 microgram of PF-05089771 |
| PF-05150122 | DRUG | single intravenous administration of 100 microgram PF-05150122 |
| PF-05241328 | DRUG | single intravenous infusion of 100 microgram PF-05241328 |
Inclusion Criteria: * healthy male subjects between the ages of 18 and 50 years inclusive. (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead ECG and clinical la...
PF-05186462 is an investigational small molecule developed by Pfizer, Inc. It has been studied in a Phase 1 clinical trial in healthy male volunteers in the United Kingdom. The compound's intended therapeutic indication has not been disclosed, and it remains in early clinical development rather than approved for any use.
PF-05186462 is made and developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United Kingdom.
PF-05186462 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The compound is investigational and has not been approved by the FDA or any other regulatory agency for commercial use.
PF-05186462 has been evaluated in one clinical trial, NCT01165736, titled to calculate the pharmacokinetics following a very low dose of compound which will not have any pharmacological activity. The Phase 1 study enrolled 40 healthy male volunteers in the United Kingdom, was randomized and active controlled, and has been completed.
The Phase 1 trial NCT01165736 evaluated the pharmacokinetics of PF-05186462, meaning the concentration of the compound in the blood and its rate of excretion. It used a very low dose intended to have no pharmacological activity, enrolled 40 healthy male volunteers aged 18 years and older in the United Kingdom, and has been completed.